A groundbreaking injectable version of the cancer drug Keytruda is poised to significantly reduce hospital time for patients across the UK, offering a welcome advancement in cancer therapy. This new formulation promises to enhance patient experience by cutting treatment administration from over an hour to just a couple of minutes, thereby alleviating some of the pressures on the NHS.
A New Era for Cancer Treatment
Keytruda, known generically as pembrolizumab, has been a mainstay in cancer treatment since 2015, administered primarily via intravenous infusion. This method, while effective, required patients to spend extended periods in hospital for treatment, often leading to fatigue and inconvenience. With the launch of the injectable form, NHS England anticipates a transformation in how patients receive this life-saving therapy.
Shirley Xerxes, an 86-year-old from St Albans, was one of the first patients to experience this new method at the Mount Vernon Cancer Centre. “I was in the chair for a matter of minutes instead of an hour or more,” she shared. “It’s made such a difference and gives me more time to live my life, including spending more time gardening.” Her testimony highlights the profound impact of this development on patient quality of life.
Key Features of the Injectable Formulation
The new injectable Keytruda can be administered every three weeks in a one-minute session or every six weeks in a two-minute session, tailored to the individual patient’s cancer diagnosis. This flexibility ensures that treatment can be personalised, catering to the specific needs of approximately 14,000 patients in England who commence a course of Keytruda annually. Currently, the drug is effective against 14 different cancer types, including lung, head and neck, cervical, and breast cancers.
This innovation marks a significant progression in immunotherapy options available on the NHS, joining the ranks of other injectable treatments, such as Opdivo (nivolumab), introduced in select hospitals last year.
The Science Behind Immunotherapy
Cancer’s ability to evade the immune system, often described as donning an “invisibility cloak,” has been a major challenge in treatment. Immunotherapy, including Keytruda, works by blocking cancer cells’ mechanisms that signal to immune cells not to attack. This approach enhances the body’s natural defences against cancer, leading to improved patient outcomes. This crucial breakthrough in immunotherapy earned scientists James Allison and Tasuku Honjo the Nobel Prize in Medicine in 2018.
Keytruda, one of the first immunotherapy drugs approved, has since become the world’s best-selling prescription medication, with projected global sales reaching $30 billion (£22 billion) by 2025. Its widespread acceptance and efficacy underscore the significant role that immunotherapy plays in modern oncology.
Implications for the NHS and Patient Care
Professor Peter Johnson, NHS England’s national clinical director for cancer, emphasised the broader implications of this change. “Managing cancer treatment and regular hospital trips can be really exhausting. If we can do this in a much shorter period of time, it frees up space in our chemotherapy units and means we can start thinking about giving treatment in the community and away from hospitals.”
This shift could potentially lead to a more efficient use of NHS resources, allowing healthcare professionals to allocate time to other vital clinical tasks. While the exact cost of the injectable form remains undisclosed due to confidentiality agreements between NHS England and Merck Sharp & Dohme (MSD), it is understood the pricing will be comparable to the current infusion version.
Why it Matters
The introduction of the injectable Keytruda signifies a pivotal moment in cancer treatment within the NHS, promising to enhance patient comfort and streamline care processes. By significantly reducing the time patients spend in hospital, this innovative drug not only improves the everyday lives of those battling cancer but also optimises healthcare delivery in an increasingly strained system. As the NHS continues to adapt and evolve, advancements like this are essential for providing effective and compassionate patient care in the years to come.